posted
LITTLETON, CO--(MARKET WIRE)--Feb 23, 2004 -- Zynex Medical (OTC BB:ZYNX.OB - News) announces its FDA approval of the NeuroMove™. The NeuroMove™ is a patent pending device that assists teaching stroke victims to use healthy parts of the brain to relearn lost functionality. ADVERTISEMENT
The NeuroMove™ was cleared by the FDA specifically for stroke rehabilitation and the approval process was completed in less than 3 months late 2001, from the first application FDA to the final FDA approval. The breakthrough technology was introduced to the US market during 2003 with an overwhelming response. 4,000,000 existing and over 600,000 new stroke victims every year in the US may regain functionality from using Zynex's NeuroMove™.
Thomas Sandgaard, CEO of Zynex Medical Holdings, Inc., stated, "This FDA approval enables us to begin a large scale sales and marketing program that will hopefully generate significant value for our shareholders."
ABOUT ZYNEX MEDICAL, INC.:
Since 1996, Zynex has been a leading provider of relief for patients with functional disability through the creation, distribution and marketing of the highest quality electrotherapy products available today. Zynex continually strives to uphold its mission to improve the quality of life of patients suffering from debilitating pain or illness by providing the highest technology and service standards in the electrotherapy industry. Zynex offers patients a new lease on life through increased mobility and independence.
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
